Jacobus Pharmaceutical’s Ruzurgi (amifampridine) Receives the US FDA’s Approval for Lambert-Eaton myasthenic syndrome


  • The approval is based on the study assessing Ruzurgi vs PBO in 32 adult patients while patients taking Ruzurgi for at least three months prior to entering the study
  • The study measured effectiveness of a patient to rise from a chair, walk three meters & return to the chair for three consecutive laps without pause, self-assessment scale for LEMS-related weakness evaluating the feeling of weakening or strengthening which was more in PBO patients and patients experienced less impairment vs PBO
  • Ruzurgi tablets is a potassium chain blocker indicated for LEMS and has received FDA’s Priority Review and Fast Track designation as well as Orphan Drug Designations

Click here to read full press release/ article | Ref: Jacobus Pharmaceutical | Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post